Mannitol Is Associated with Less Postoperative Delirium after Aortic Valve Surgery in Patients Treated with Bretschneider Cardioplegia

Marwan Hamiko, Efstratios I. Charitos, Markus Velten, Tobias Hilbert, Christian Putensen, Hendrik Treede, Georg Daniel Duerr

1 Department of Cardiac Surgery, University Clinical Center Bonn, Bonn, North Rhine-Westphalia, Germany
2 Department of Anaesthesiology and Intensive Care Medicine, University Clinical Center Bonn, Bonn, North Rhine-Westphalia, Germany

Thorac Cardiovasc Surg

Abstract

**Background** Heart surgery with extracorporeal circulation (ECC) often leads to postoperative delirium (POD). This is associated with increased morbidity resulting in longer hospital stay and associated costs. The purpose of our study was to analyze the effect of intraoperative mannitol application on POD in patients undergoing elective aortic valve replacement (AVR).

**Materials and Methods** In our retrospective single-center study, 259 patients underwent elective AVR, using Bretschneider cardioplegic solution for cardiac arrest, between 2014 and 2017. Patients were divided in mannitol (n = 188) and nonmannitol (n = 71) groups. POD was assessed using the confusion assessment method for the intensive care unit (ICU). Statistical significance was assumed at p < 0.05.

**Results** Baseline patient characteristics did not differ between the groups. Incidence of POD was significantly higher in the nonmannitol group (33.8 vs. 13.8%; p = 0.001). These patients required longer ventilation time (24.1 vs. 17.1 hours; p = 0.021), higher reintubation rate (11.3 vs. 2.7%; p = 0.009), ICU readmission (12.7 vs. 4.8%; p = 0.026), prolonged ICU (112 vs. 70 hours; p = 0.040), and hospital stay (17.8 vs. 12.6 days; p < 0.001), leading to higher expenses (19,349 € vs. 16,606 €, p < 0.001). A 30-day mortality was not affected, but nonmannitol group showed higher Simplified Acute Physiology Score II score (32.2 vs. 28.7; p < 0.001). Mannitol substitution was independently associated with lower incidence of POD (odds ratio: 0.40; 95% confidence interval: 0.18–0.89; p = 0.02).

**Conclusion** Treatment with mannitol during ECC was associated with decreased incidence of POD. This was accompanied by shorter ventilation time, ICU and hospital stay, and lower treatment expenses.

Introduction

Postoperative delirium (POD) is a common neurological complication after surgery, most often seen in elderly patients. Besides age, cardiac function, diabetes, vascular disease, and pre-existent cognitive impairment, POD is also independently associated with invasiveness and duration of cardiac surgery. In this regard, patients undergoing cardiopulmonary bypass (CPB) seem to be vulnerable for the development of POD, which is diagnosed in ≈30 to 52% in this population. Most notably, POD is associated with longer intensive care unit (ICU) and hospital stay, long-term cognitive impairment, and...
increased mortality, consequently leading to increase in treatment expenses. Therefore, attempts to reduce POD in these patients are important.

It has been reported that CPB itself can promote the development of POD. Preparation of the CPB is not uniform: hypo-oncotic priming solutions of the heart–lung machine (HLM) can result in interstitial fluid retention and lead to cerebral edema; the latter has been shown to promote encephalopathy and delirium, but the underlying mechanism remains unclear. In contrast, an increased oncotic pressure is beneficial for maintaining a sufficient mean arterial pressure (MAP) and has been shown to improve organ perfusion. As a consequence, colloids such as human albumin (HA) or hydroxyethyl starch (HES) are often added to the priming solution of the HLM. However, a clear advantage for using colloidal solutions could not be demonstrated. Moreover, studies report that the use of HES and HA are associated with renal failure, even though conflicting data exist with respect to nephroprotective properties of HA, showing reduced risk of acute renal failure after off-pump coronary artery bypass surgery. Most importantly, HES administration was related to early POD development.

Mannitol is commonly used to reduce intracranial pressure and edema due to its osmotic effects and may be added to the priming solution during CPB to maintain higher oncotic pressure. But so far, no study has examined an association between mannitol application during CPB and POD. Therefore, this study aimed to examine the effect of mannitol supplementation during CPB on the development of POD and other parameters of postoperative outcome in a homogenous cohort of patients undergoing elective surgical aortic valve replacement (AVR).

Materials and Methods

Patient Selection and Group Definition

This retrospective single-center study was performed on 259 patients, who were admitted for first time elective surgical AVR between 2014 and 2017. Indications for AVR were aortic stenosis, aortic regurgitation, or elective AVR. All patients undergoing concomitant heart surgeries (e.g., coronary artery bypass graft surgery, other valve procedures, etc.) or David/Bentall procedures were excluded from the study. One patient was diagnosed with aortic valve endocarditis, but this was not associated with enhanced inflammatory parameters and only diagnosed in echocardiography. In all patients included in our study, retrograde autologous priming (RAP) of the HLM was performed. All patients receiving albumin or crystalloid priming were excluded from this study. A comprehensive dataset of pre-, intra-, and postoperative parameters was generated by review of patient charts and IT-based datasets. Information on preoperative baseline characteristic, risk factors, and comorbidities, such as renal (need for hemodialysis) or liver failure, were recorded. Also, we screened all available preoperative patient’s data (recent medical reports, information provided by the patients and/or family members) with respect to cerebrovascular insults, neurological and cognitive impairment (e.g., preexisting dementia, Alzheimer’s and Parkinson’s disease, epilepsy), psychiatric or mental disorders (e.g., schizophrenia, depression), daily medication, and drug or alcohol abuse.

Within the aforementioned period of time, all patients, except those with complicated preoperative course, for example, organ failure, preoperative catecholamine therapy, the need for mechanical circulatory support (MCS), or the above-described psychic or mental disorders and drug or alcohol abuse, were included in this study. The preoperative risk score European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) was calculated for each patient. All patients who were eligible for this retrospective study were divided into two groups: 188 patients having received mannitol during CPB (mannitol group) and 71 patients having not received (nonmannitol group).

Surgical Procedure and Mannitol Administration

All patients were classified as American Society of Anesthesiologists III and IV, and a standard anesthetic protocol was performed using sufentanil, etomidate, and rocuronium for induction of anesthesia followed by endotracheal intubation. Anesthesia was maintained using sufentanil and sevoflurane. Standard monitoring comprised peripheral oxygen saturation, electrocardiogram, temperature, and invasive arterial blood pressure. Furthermore, a trilumen central venous catheter, a high-flow sheath introducer, as well as a urinary catheter was placed. During CPB, sevoflurane was administered continuously during CPB. Surgical procedure was similar in all patients: complete median or superior median ministernotomy was performed. To achieve an activating clotting time of >450 seconds, anticoagulation with 400 to 500 U/kg sodium heparin was initiated. After cannulation of the ascending aorta and the right atrium, CPB was established using a Terumo Advanced Perfusion System 1 (Terumo Cardiovascular Systems, Ann Arbor, Michigan, United States). The extracorporeal circuit included a venous hardshell cardiomyotomy reservoir (Maquet, Wayne, New Jersey, United States), a roller pump system, and a membrane oxygenator (Quadrox oxygenator, Maquet) equipped with a heat exchanger and an arterial filter system. The nonheparin-coated tube system was primed with crystalloid solution (~1,000 mL Jonosteril, Fresenius, Bad Homburg, Germany) and 10,000 U of heparin. In all patients, RAP was performed after connecting the HLM to the introduced cannulas.

In this study, 188 patients were treated with 0.5 g/kg body weight mannitol solution (OsmoSteril 20%, Fresenius-Kabi GmbH, Bad Homburg, Germany) during extracorporeal circulation (ECC) according to intraoperative diuresis and fluid intake: If intraoperative diuresis was less than 50 mL/h after aortic unclamping and/or more than 3,000 mL crystalloid solution were infused during ECC, mannitol was administered as bolus into the HLM to augment diuresis and to minimize fluid movement to the extravascular space. All other patients did not receive mannitol. The mannitol dosage was in accordance with other studies. Mannitol was not part of the priming solution, as no effects of mannitol on osmolality of the priming solution have been observed in patients with normal cardiac and renal function. Cardioprotection and myocardial arrest were achieved using Bretschneider HTK-cardioplegia (Custadiol, Dr. Franz Kohler
Mannitol Is Associated with Less POD after Aortic Valve Surgery in Patients

Hamiko et al.

Chemie GmbH, Bensheim, Germany). A nonpulsatile pump flow of 2.2 to 2.6 L/min/m² was conducted to maintain a MAP of 50 to 60 mm Hg during CPB.

Postoperative Care
After the surgical procedure, all patients were transferred to the ICU, where sedation was achieved using propofol and sufentanil. Airway pressure release ventilation was performed, with an inspiratory-expiratory ratio of 1.5:2 seconds, corresponding to a respiratory rate of 17 breaths/min. Tidal volume of 6 to 8 mL/kg was used, and positive inspiratory pressure was set to 20 cm H₂O, while positive end-expiratory pressure of 10 cm H₂O was applied. The fraction of insufflated oxygen was adjusted according to arterial blood gas analysis. Early extubation and transfer to the intermediate care ward were attempted in all cases. Further analgesic regimen followed piritramide bolus injection (3–5 mg intravenous).

Duration of surgery, CPB and aortic cross-clamping time, parameters of organ function, and other routine laboratory variables were recorded. Outcome data further included: ventilator-associated pneumonia, need for reintubation, renal failure with need for continuous venovenous hemofiltration or -dialysis (CVVH/HD, length of ICU and hospital stay, nurse workload score (“Therapeutic Intervention Scoring System” [TISS]-10), and monitoring of the “Simplified Acute Physiology Score II” (SAPS II), as well as 30-day mortality and the total hospital treatment costs.

Assessment of Postoperative Delirium
For assessment of POD, criteria of the Diagnostic and Statistical Manual of Mental Disease, Fifth Edition were applied. Delirium is characterized by fluctuating clinical course, for example, memory deficit, disorientation, language, visuospatial ability, or perception disorders. The development of delirium within short time was assessed daily during ICU stay using the confusion assessment method for the intensive care unit (CAM-ICU) flowsheet. Patients with sedation (“Richmond Agitation and Sedation Scale” score < –3), stroke symptoms, or nonnative German speakers were excluded from the study. Patients with a positive CAM-ICU test were defined as POD positive.

Statistical Analysis
Data are presented as means with standard deviation. Continuous variables were tested using either the Student’s t-test, or, in the case of a nonnormal distribution (D’Agostino’s K-squared test), the Mann–Whitney’s U test. Linear mixed models were used to investigate differences between mannitol and nonmannitol groups on the time course of various parameters of interest measures (lactate, serum creatinine, and bilirubin). Categorical data were expressed as percentages and tested using the Pearson’s chi-square test. A p-value of <0.05 was considered statistically significant.

Univariable and multivariable logistic regression were employed to investigate risk factors for POD. The following risk factors were investigated: Patients age, diabetes mellitus, white blood cell (WBC) at admission, preoperative sodium, creatinine, hemoglobin and hematocrit values, EuroScore II, aortic cross-clamping time, CPB time, reperfusion time, minimum and mean sodium concentrations during CPB, minimum intraoperative hemoglobin, minimum intraoperative arterial oxygen saturation, minimum intraoperative MAP, mannitol substitution during CPB, amount of cardioplegic solution, fluid balance after CPB, amount of blood products transfusion during surgery, total diuresis during CPB, perioperative ventilation time, need for postoperative reintubation, need for postoperative CVVH/HD or dialysis, pneumonia, SAPS II score 24 hours after ICU admission, postoperative maximum creatinine, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and MAP 1 hour after surgery.


Results
No significant differences in terms of demographic and preoperative baseline characteristics were observed between the two groups: Most importantly, no differences were seen in pre- and postoperative serum creatinine, bilirubin, and ALT/AST levels (Table 1 and Supplementary Table S1 [online only]), indicating no differences in renal and liver function in both groups. The pre- and postoperative lactate levels as parameter for an anaerobic metabolism and thus surrogate parameter of reduced organ perfusion did not show any significant difference between the groups. Also, the hemoglobin concentration, WBC, and platelet count before and after surgery were not different (Table 1 and Supplementary Table S1 [online only]).

Table 2 summarizes intraoperative data, sowing no differences with respect to duration of surgery, aortic cross-clamping time and CPB time, MAP, and amount of cardioplegic solution. Fluid balance during CPB was significantly less positive in the mannitol compared with the nonmannitol patients, being associated with higher diuresis and filtered fluid amount in the same group. No difference was observed with respect to intraoperatively transfused red blood cell concentrates. Beside hemoglobin and lactate concentration, minimum and mean serum sodium concentrations during CPB were similar in both groups, going along with comparable postoperative diuresis and total fluid balance after 24 hours (Supplementary Table S1 [online only]).

Further, data on postoperative outcome and adverse events are displayed in Table 3 and Supplementary Table S1 (online only): no difference was seen with respect to use of MCS, need for cardiopulmonary resuscitation, incidence of pneumonia, number of postoperative myocardial infarction, atrioventricular block higher than second degree, need for pacemaker implantation, CVVH/D, and rethoracotomy. However, most importantly, the incidence of POD was significantly higher in the nonmannitol compared with the mannitol group. Furthermore, absence of mannitol was associated with longer...
# Table 1 Preoperative patients' characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 259)</th>
<th>Mannitol (n = 188)</th>
<th>Nonmannitol (n = 71)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>66.6 ± 10.2</td>
<td>66.0 ± 10.8</td>
<td>67.9 ± 8.1</td>
<td>0.182</td>
</tr>
<tr>
<td>Female</td>
<td>88 (34.0%)</td>
<td>64 (34.0%)</td>
<td>24 (33.8%)</td>
<td>0.971</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.74 ± 0.3</td>
<td>1.72 ± 0.1</td>
<td>1.80 ± 0.7</td>
<td>0.126</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82.7 ± 15.2</td>
<td>82.4 ± 15.1</td>
<td>83.5 ± 15.5</td>
<td>0.603</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.2 ± 9.2</td>
<td>27.8 ± 4.8</td>
<td>29.3 ± 15.8</td>
<td>0.248</td>
</tr>
<tr>
<td>EuroSCORE II</td>
<td>1.83 ± 0.75</td>
<td>1.80 ± 0.69</td>
<td>1.92 ± 0.90</td>
<td>0.207</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>56/253 (22.1%)</td>
<td>39/183 (21.3%)</td>
<td>17 (24.3%)</td>
<td>0.610</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>13.4 ± 1.9</td>
<td>13.5 ± 1.8</td>
<td>13.3 ± 1.9</td>
<td>0.502</td>
</tr>
<tr>
<td>WBC (g/L)</td>
<td>7.6 ± 2.5</td>
<td>7.7 ± 2.5</td>
<td>7.4 ± 2.5</td>
<td>0.490</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.1 ± 0.6</td>
<td>1.0 ± 0.4</td>
<td>1.1 ± 0.9</td>
<td>0.341</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>0.7 ± 0.6</td>
<td>0.7 ± 0.7</td>
<td>0.6 ± 0.4</td>
<td>0.435</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>31.0 ± 15.6</td>
<td>31.5 ± 15.1</td>
<td>29.1 ± 17.1</td>
<td>0.455</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>26.7 ± 17.3</td>
<td>27.1 ± 18.9</td>
<td>25.3 ± 11.2</td>
<td>0.508</td>
</tr>
</tbody>
</table>

Left ventricular ejection fraction

- > 50%: 218 (84.1%) 154 (81.9%) 64 (90.1%) 0.296
- 30–50%: 35 (13.5%) 29 (15.4%) 6 (8.5%) 0.607
- < 30%: 6 (2.3%) 5 (2.7%) 1 (1.4%) 0.455

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; Mannitol, patients received mannitol during extracorporeal circulation; Nonmannitol, patients without mannitol treatment; WBC, white blood cell.

**Notes:** Summary of preoperative patients’ characteristics. Values are expressed as mean ± standard deviation, or as number and percentage (in bracket). Significant changes are displayed in italics.

# Table 2 Intraoperative data

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 259)</th>
<th>Mannitol (n = 188)</th>
<th>Nonmannitol (n = 71)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to skin closure (min)</td>
<td>230.6 ± 58.7</td>
<td>232.0 ± 59.2</td>
<td>226.8 ± 57.7</td>
<td>0.284</td>
</tr>
<tr>
<td>CPB time (min)</td>
<td>120.8 ± 111.4</td>
<td>115.0 ± 29.4</td>
<td>112.5 ± 24.5</td>
<td>0.695</td>
</tr>
<tr>
<td>Aortic clamp time (min)</td>
<td>86.8 ± 41.0</td>
<td>85.2 ± 21.3</td>
<td>82.7 ± 18.8</td>
<td>0.607</td>
</tr>
<tr>
<td>Cardioplegic solution (mL)</td>
<td>1,776.8 ± 354.9</td>
<td>1,792.2 ± 384.6</td>
<td>1,735.9 ± 258.3</td>
<td>0.671</td>
</tr>
<tr>
<td>Fluid balance on CPB (mL)</td>
<td>223.5 ± 1,240.5</td>
<td>132.5 ± 21.3</td>
<td>464.6 ± 922.7</td>
<td>0.006</td>
</tr>
<tr>
<td>Diuresis during CPB (mL)</td>
<td>369.8 ± 339.0</td>
<td>386.3 ± 326.0</td>
<td>326.3 ± 370.1</td>
<td>0.022</td>
</tr>
<tr>
<td>MAP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum (mm Hg)</td>
<td>54.6 ± 8.6</td>
<td>54.4 ± 9.0</td>
<td>55.1 ± 7.6</td>
<td>0.578</td>
</tr>
<tr>
<td>Maximum (mm Hg)</td>
<td>67.0 ± 9.1</td>
<td>66.6 ± 9.3</td>
<td>68.0 ± 8.3</td>
<td>0.098</td>
</tr>
<tr>
<td>Hemoglobin concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum (g/dL)</td>
<td>9.58 ± 1.61</td>
<td>9.54 ± 1.63</td>
<td>9.70 ± 1.55</td>
<td>0.523</td>
</tr>
<tr>
<td>Maximum (g/dL)</td>
<td>11.11 ± 1.40</td>
<td>11.14 ± 1.43</td>
<td>11.05 ± 1.30</td>
<td>0.981</td>
</tr>
<tr>
<td>Serum sodium during CPB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (mmol/L)</td>
<td>132.40 ± 3.90</td>
<td>132.29 ± 3.83</td>
<td>128.18 ± 6.07</td>
<td>0.480</td>
</tr>
<tr>
<td>Minimum (mmol/L)</td>
<td>128.54 ± 5.86</td>
<td>132.69 ± 4.09</td>
<td>129.51 ± 5.19</td>
<td>0.080</td>
</tr>
<tr>
<td>RCC (units)</td>
<td>0.35 ± 0.77</td>
<td>0.32 ± 0.71</td>
<td>0.42 ± 0.90</td>
<td>0.625</td>
</tr>
<tr>
<td>Maximum lactate (mmol/L)</td>
<td>1.53 ± 1.89</td>
<td>1.60 ± 2.20</td>
<td>1.35 ± 0.51</td>
<td>0.444</td>
</tr>
</tbody>
</table>

**Abbreviations:** CPB, cardiopulmonary bypass; MAP, mean arterial pressure; Mannitol, patients received mannitol during extracorporeal circulation; Nonmannitol, patients without mannitol treatment; RCC, red blood cell concentrate.

**Notes:** Summary of surgery-related intraoperative variables. Values are expressed as mean ± standard deviation. Significant changes are displayed in italics.

---

*Thoracic and Cardiovascular Surgeon*
In multivariable regression analysis, mannitol was an independent and statistically significant factor associated with lower incidence of POD (Table 5). A visualization of this model using prototypical values is shown in Fig. 1. A receiver operating characteristics analysis was performed to investigate the discrimination ability of our model. Our model showed an area under the curve of 0.84 (Fig. 2; 95% confidence interval: 0.78–0.91; p < 0.001). Recursive partitioning was utilized to investigate and visualize the influence of mannitol on POD and is displayed in Fig. 3.

### Discussion

In this study, we were able to show that mannitol administration during ECC decreases the incidence of POD in patients undergoing AVR. POD is a severe postoperative neurological complication being associated with increased morbidity and mortality, longer hospital stays, and enhanced medical costs. Accordingly, we show that nurse workload index TISS-10, mortality predicting SAPS II, duration of mechanical ventilation, duration of ICU and hospital stays,

### Table 3 Postoperative outcome

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 259)</th>
<th>Mannitol (n = 188)</th>
<th>Nonmannitol (n = 71)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>POD, n (%)</td>
<td>50 (19.3%)</td>
<td>26 (13.8%)</td>
<td>24 (33.8%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Reintubation</td>
<td>13 (5.1%)</td>
<td>5 (2.7%)</td>
<td>8 (11.3%)</td>
<td>0.009</td>
</tr>
<tr>
<td>SAPS II score 24 h</td>
<td>29.7 ± 7.2</td>
<td>28.7 ± 7.1</td>
<td>32.2 ± 7.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ventilation time (h)</td>
<td>19.0 ± 33.9</td>
<td>17.1 ± 33.1</td>
<td>24.1 ± 35.6</td>
<td>0.021</td>
</tr>
<tr>
<td>ICU stay (h)</td>
<td>81.5 ± 147.3</td>
<td>70.0 ± 110.2</td>
<td>112.0 ± 214.7</td>
<td>0.040</td>
</tr>
<tr>
<td>Readmission to ICU</td>
<td>18 (6.9%)</td>
<td>9 (4.8%)</td>
<td>9 (12.7%)</td>
<td>0.026</td>
</tr>
<tr>
<td>In-hospital stay postop (d)</td>
<td>14.5 ± 12.8</td>
<td>12.6 ± 9.7</td>
<td>17.8 ± 11.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment expenses (€)</td>
<td>17,351 ± 5,168</td>
<td>16,606 ± 3,842</td>
<td>19,349 ± 7,341</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>30-d mortality</td>
<td>7 (2.7%)</td>
<td>7 (3.7%)</td>
<td>0 (0.0%)</td>
<td>0.099</td>
</tr>
</tbody>
</table>

Abbreviations: ICU, intensive care unit; Mannitol, patients received mannitol during extracorporeal circulation; Nonmannitol, patients without mannitol treatment; POD, postoperative delirium; postop, postoperative; SAPS II, Simplified Acute Physiology Score II.

### Table 4 Comparison between delirious and nondelirious patients

<table>
<thead>
<tr>
<th></th>
<th>Delirium (n = 50)</th>
<th>Nondelirium (n = 209)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>14 (28.0%)</td>
<td>7 (3.3%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Reintubation</td>
<td>11 (22.0%)</td>
<td>2 (1.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SAPS II score 24 h</td>
<td>35.0 ± 7.3</td>
<td>28.4 ± 6.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TISS-10 score 24 h</td>
<td>24.6 ± 4.6</td>
<td>19.3 ± 6.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ventilation time (h)</td>
<td>31.6 ± 39.4</td>
<td>16.0 ± 31.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICU stay in h</td>
<td>193.6 ± 234.9</td>
<td>54.6 ± 100.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Readmission to ICU</td>
<td>15 (30.0%)</td>
<td>3 (1.4%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>In-hospital stay postop (d)</td>
<td>20.2 ± 18.9</td>
<td>18.4 ± 76.4</td>
<td>0.003</td>
</tr>
<tr>
<td>Treatment expenses (€)</td>
<td>21,625 ± 8,733</td>
<td>16,326 ± 3,113</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>30-d mortality</td>
<td>1 (2.0%)</td>
<td>6 (2.9%)</td>
<td>0.116</td>
</tr>
</tbody>
</table>

Abbreviations: ICU, intensive care unit; postop, postoperative; SAPS II, Simplified Acute Physiology Score II; TISS, Therapeutic Intervention Scoring System.

Notes: Summary of data on postoperative outcome and adverse events compared between delirious and nondelirious patients. Values are expressed as mean ± standard deviation, or as number and percentage (in bracket). Significant changes are displayed in italics.

### Table 5 Multivariable logistic regression model

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR</th>
<th>95% CI</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>0.0061</td>
<td>0.0008–0.0383</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mannitol substitution</td>
<td>0.4025</td>
<td>0.1815–0.8930</td>
<td>0.02</td>
</tr>
<tr>
<td>Reintubation</td>
<td>9.0824</td>
<td>1.9884–65.2400</td>
<td>0.009</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>5.0479</td>
<td>1.4688–17.7855</td>
<td>0.009</td>
</tr>
<tr>
<td>SAPS II score 24 h</td>
<td>1.0962</td>
<td>1.0381–1.1620</td>
<td>0.001</td>
</tr>
<tr>
<td>EuroSCORE II</td>
<td>1.6755</td>
<td>1.0754–2.6725</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; OR, odds ratio; SAPS II, Simplified Acute Physiology Score II.

Notes: Results of the multivariate logistic regression analysis. Significant changes are displayed in italics.
readmission to ICU, and incidence for pneumonia were significantly higher in patients suffering from POD after AVR. Further, POD was associated with significantly enhanced medical costs, which has also been reported after major urological surgery.\textsuperscript{27} POD, particularly its hypoactive form, is often overlooked during ICU, which could be associated with far-reaching consequences.\textsuperscript{30} We applied the CAM-ICU test that has been proven to be suitable for POD screening of postcardiotomy patients.\textsuperscript{24} In this regard, early recognition and treatment of POD have been demonstrated to be key for the reduction, duration, and severity of POD with associated negative outcomes.\textsuperscript{31}

Various studies have investigated predisposing and precipitating factors of POD in postcardiotomy patients.\textsuperscript{32,33} Beside individual patient conditions, procedure-associated factors, such as the complexity of surgery, and consequently, duration of ECC have been identified as independent predisposing factors for postcardiotomy POD.\textsuperscript{34,35} Also, besides their association with postoperative renal failure, the use of HES and HA as HLM priming solutions is related to early POD.\textsuperscript{18} Although RAP is the standard procedure in many hospitals, the HLM tubing system is primed with crystalloid solution, potentially resulting in a drop in oncotic pressure. With respect to the kidney-related disadvantages of HES, mannitol has been used during ECC for years to maintain an elevated oncotic pressure and a more stable MAP.

While most studies have focused on the effect of mannitol on postoperative renal failure,\textsuperscript{36,37} we investigated the impact of mannitol substitution on POD and postoperative outcome in a cohort of postcardiotomy patients undergoing elective AVR. Patients with preexisting mental conditions were excluded. Our data reveal no differences with respect to preoperative demographic characteristics, organ function, coagulation, and inflammation parameters between the mannitol and the non-mannitol groups. Also, EuroSCORE II was not different. Most importantly, we show in multivariable regression analysis that mannitol was an independent and statistically significant factor associated with lower incidence of POD; while POD incidence in nonmannitol patients was in accordance with other studies.\textsuperscript{3,33} Mannitol supplementation was associated with only 13.8% POD in patients with a comparable ECC and aortic cross-clamping time. A visualization of our model showed significantly lower probability of POD independent of the operative risk stratification of the patient (EuroSCORE II), need for reintubation, development of pneumonia, or SAPS II 24 hours score. Recursive partitioning was utilized to visualize the influence of mannitol on POD, showing that with increasing EuroSCORE II, mannitol treatment is associated with lower incidence of POD. Furthermore, lower incidence of POD in the mannitol group was accompanied by shorter ventilation time, ICU and total hospital stay, lower ICU readmission rate, and reintubation rate and lower SAPS II score. The 30-day mortality was not affected.

Against the background of increasing shortage of health care professionals, identification and elimination of modifiable risk factors and potentially preventing POD in

**Fig. 1** A visualization of our multivariable model (– Table 5) using prototypical values for reintubation, EuroSCORE II, mannitol substitution and SAPS II score. EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; ICU, intensive care unit; POD, postoperative delirium; SAPS II, Simplified Acute Physiology Score II.
Fig. 2  ROC analysis for delirium and mannitol substitution. The ROC curve and the AUC show a good discrimination ability of our multivariable model (AUC: 0.84; 95% CI: 0.78–0.91; p < 0.001). AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic.

Fig. 3  Recursive partitioning and conditional inference trees. An analysis with recursive partitioning and conditional inference trees showing the influence of mannitol on POD in all EuroSCORE II groups. EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; POD, postoperative delirium.
Mannitol is Associated with Less POD after Aortic Valve Surgery in Patients

Hamiko et al.

Thoracic and Cardiovascular Surgeon

postcardiomyoplasty patients have a high priority. From the economic perspective, longer ventilation time with prolonged ICU stay causes increased treatment expenses.\textsuperscript{5,7,26} Our data are in line with previous studies, connecting POD to longer hospitalization time and higher treatment expenses after major surgeries.\textsuperscript{7,27} Moreover, we could show that mannitol substitution was associated with significantly reduced treatment costs. Therefore, our data suggest that patients with no mannitol treatment have a higher probability for development of POD, causing higher need for ICU stay, which in return leads to lower number of surgeries. Besides higher treatment expenses, this potentially contributes to lower earnings of the surgical department.

In the past, effects of mannitol administration during cardiac surgery have been studied focusing on postoperative acute renal failure, showing that mannitol has no effect on renal function during cardiac surgery in patients with or without established renal dysfunction.\textsuperscript{36,37} In agreement with this, we did not observe signs of renal failure after mannitol administration, as demonstrated by comparable postoperative maximum serum creatinine values, accompanied by comparable total diuresis and fluid balance after 24 hours in both groups. Also, the trend of serum creatinine as well as the need for CVVH has been similar between the two groups. These data are in line with the above-cited studies showing neither advantage nor disadvantage of mannitol substitution on renal function; also, the effect of mannitol removal from the priming solution based on observations of high volume and potassium requirements resulting from excessive diuresis did not have any effect on electrolytes, fluid status, and other outcomes in another study.\textsuperscript{38}

Furthermore, a potential role of the sodium shift induced by Bretschneider solution for induction of POD by inducing an acute hyponatremia has to be considered, as Aldemir et al reported that hyponatremia is a predicting factor for delirium in a surgical ICU.\textsuperscript{39} In this regard, univariable and multivariable logistic regression showed that both mean and minimum serum sodium concentration during CPB were not independently associated with incidence of POD in our study. This suggests that the use of hyponatremic Bretschneider cardioplegic solution has no impact on prevalence of POD.

With respect to possible underlying mechanisms, it is known that CPB promotes systemic inflammatory response syndrome due to activation of the complement system, resulting in a reaction including cytokines release, leukocyte activation, and ROS generation.\textsuperscript{40} This cascade leads to endothelial dysfunction leading to interstitial edema. This may disrupt the blood–brain barrier and result in neuroinflammation with activation of microglial cells.\textsuperscript{41} Neuroinflammation itself leads to fluid accumulation and swelling, favoring POD.\textsuperscript{42} Here, this mechanistic concept of mannitol use to reduce cell edema could be transferred to cardiac surgery. Further, it has been shown that mannitol reduces the plasma levels of ROS;\textsuperscript{43} and reportedly, antioxidant therapy with mannitol during CPB induced immunosuppression after coronary artery bypass graft surgery.\textsuperscript{22} In this light, mannitol might also exert its antidelirious effect via suppression of neuroinflammation. But an examination of the underlying mechanisms of mannitol treatment and its connection to POD were beyond the scope of this study.

In summary, our data suggest that mannitol supplementation should be considered in patients undergoing CPB. However, the appropriate dosage should be accredited in patients with impaired renal function.

Limitation of the Study

Our study is limited due to its retrospective character, resulting in unequally sized patient groups. An additional limitation of the study is the lack of preoperative cognitive assessment and evaluation of preoperative delirium using common confusion assessment methods such as the Montreal Confusion Assessment or Mini–Mental Test. In addition, we do not provide data on postoperative quality of life. Regarding the use of Bretschneider cardioplegic solution and associated intraoperative hyponatremia during CPB, we acknowledge that the beneficial effects of mannitol may not be observed in patients treated with modern blood cardioplegia solutions (e.g., Buckberg, Calafiore, etc.). Therefore, any conclusions will need to be proven by a randomized controlled trial.

Conclusion

Early recognition of POD is important since it is associated with worse postoperative outcome, prolonged ICU and hospital stay, and thus higher treatment expenses. Our study shows for the first time that supplementation with mannitol during ECC is associated with lower incidence of POD in elective AVR. The 30-day mortality and other serious postoperative complications, especially renal failure, were comparable. Considering mannitol use during CPB could lead to less POD and might result in significant cost savings.

Source of Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

None declared.

Acknowledgments

M. Hamiko and E.I. Charitos contributed equally to the manuscript; M. Hamiko was mainly involved in the preparation of the data and drafting of the manuscript, while E. I. Charitos performed the statistical analysis and was involved in study design.

References